Everolimus

Generic Name
Everolimus
Brand Names
Afinitor, Votubia, Zortress
Drug Type
Small Molecule
Chemical Formula
C53H83NO14
CAS Number
159351-69-6
Unique Ingredient Identifier
9HW64Q8G6G
Background

Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Indication

Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.

Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease.

Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.

Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.

Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.

Associated Conditions
Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
Associated Therapies
-
Clinical Trials
Related News

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab

First Posted Date
2014-09-25
Last Posted Date
2017-11-13
Lead Sponsor
iOMEDICO AG
Target Recruit Count
85
Registration Number
NCT02248571
Locations
🇩🇪

iOMEDICO AG, Freiburg, Baden-Wuerttemberg, Germany

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

First Posted Date
2014-09-16
Last Posted Date
2019-01-04
Lead Sponsor
University of California, Davis
Target Recruit Count
20
Registration Number
NCT02240719
Locations
🇺🇸

University of California Davis, Sacramento, California, United States

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

Phase 2
Terminated
Conditions
Breast Cancer
Interventions
Drug: Everolimus
First Posted Date
2014-09-10
Last Posted Date
2022-02-01
Lead Sponsor
Yale University
Target Recruit Count
17
Registration Number
NCT02236572
Locations
🇺🇸

Yale University, New Haven, Connecticut, United States

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

First Posted Date
2014-09-08
Last Posted Date
2018-07-23
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
250
Registration Number
NCT02233049
Locations
🇫🇷

Gustave Roussy, Villejuif, Val De Marne, France

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

First Posted Date
2014-08-29
Last Posted Date
2024-01-03
Lead Sponsor
GOG Foundation
Target Recruit Count
74
Registration Number
NCT02228681
Locations
🇺🇸

Magee Women's Hospital of UPMC, Pittsburgh, Pennsylvania, United States

🇺🇸

University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States

🇺🇸

Women's Cancer Center of Nevada, Las Vegas, Nevada, United States

and more 23 locations

A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer

First Posted Date
2014-08-15
Last Posted Date
2024-12-02
Lead Sponsor
Queen Mary University of London
Target Recruit Count
333
Registration Number
NCT02216786
Locations
🇬🇪

Tbilisi Cancer Center, Tbilisi, Georgia

🇵🇹

Ipo Porto, Porto, Portugal

🇭🇺

Bacs-Kiskun County Hospital, Kalocsa, Hungary

and more 76 locations

An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis

Phase 1
Completed
Conditions
Carcinoma, Neuroendocrine
Interventions
Drug: Everolimus
First Posted Date
2014-07-31
Last Posted Date
2022-08-19
Lead Sponsor
Sunnybrook Health Sciences Centre
Target Recruit Count
17
Registration Number
NCT02205515
Locations
🇨🇦

Odette Cancer Centre, Sunnybrook Health Science Centre, Toronto, Ontario, Canada

Everolimus for Cancer With TSC1 or TSC2 Mutation

Phase 2
Completed
Conditions
TSC1
Tuberous Sclerosis Complex
MTOR
TSC2
Interventions
Drug: Everolimus
First Posted Date
2014-07-28
Last Posted Date
2020-09-16
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
30
Registration Number
NCT02201212
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation

First Posted Date
2014-07-14
Last Posted Date
2020-09-22
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
15
Registration Number
NCT02188719
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

Everolimus for Children With Recurrent or Progressive Ependymoma

Phase 2
Completed
Conditions
Recurrent Childhood Ependymoma
Interventions
Drug: Everolimus
First Posted Date
2014-06-04
Last Posted Date
2024-05-08
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
11
Registration Number
NCT02155920
Locations
🇺🇸

UT Southwestern Medical Center / Children's Medical Center, Dallas, Texas, United States

🇺🇸

Baylor College of Medicine / Texas Children's Hospital, Houston, Texas, United States

🇺🇸

Lucile Packard Children's Hospital Stanford University, Stanford, California, United States

and more 1 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy